Expand VALN Menu
VALN MENU

VALN Latest Press Releases

-- March 9, 2026 --

Valneva to Report Full Year 2025 Consolidated Financial Results on March 18, 2026 Globe Newswire 12:45 PM

-- March 2, 2026 --

Valneva to Participate in Upcoming Investor Conferences Globe Newswire 11:45 AM

-- February 19, 2026 --

Valneva Reports Preliminary Unaudited 2025 Revenue and Cash and Provides 2026 Outlook Globe Newswire 1:00 AM

-- February 13, 2026 --

Valneva Provides Update on Recommendations for Use of IXCHIQ in the United Kingdom Globe Newswire 11:45 AM

-- February 3, 2026 --

Valneva and Instituto Butantan Announce Initiation of a Pilot Vaccination Campaign in Brazil with Single-Shot Chikungunya Vaccine IXCHIQ Globe Newswire 1:00 AM

-- January 19, 2026 --

Valneva Provides Update on Chikungunya Vaccine IXCHIQ Globe Newswire 12:00 PM

-- January 9, 2026 --

Valneva to Meet with Investors during the J.P. Morgan Healthcare Conference Globe Newswire 1:00 AM

-- December 10, 2025 --

Valneva Reports Positive Final Phase 2 Antibody Persistence and Safety Results in Children for its Chikungunya Vaccine IXCHIQ Globe Newswire 11:45 AM

-- November 26, 2025 --

Valneva to Further Consolidate its Operations in France Globe Newswire 11:30 AM
Valneva Announces Positive Final Phase 2 Results for Lyme Disease Vaccine Candidate Globe Newswire 1:00 AM

-- November 20, 2025 --

Valneva Reports Nine-Month 2025 Financial Results and Provides Corporate Updates Globe Newswire 1:00 AM

-- November 4, 2025 --

Valneva Reports Positive Results for Phase 1 Trial of Second-Generation Zika Vaccine Candidate Globe Newswire 1:00 AM

-- October 27, 2025 --

Valneva to Present and Hold Investor Meetings at Upcoming U.S. and European Healthcare Conferences Globe Newswire 12:45 PM

-- October 18, 2025 --

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALN PRNewswire 10:00 AM
Market Data Delayed 15 Minutes